Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd(The Ohio State University), Richard R. Furman(Memorial Sloan Kettering Cancer Center), Jennifer A. Woyach(The Ohio State University), Jennifer R. Brown(Dana-Farber Cancer Institute), Amy J. Johnson(The Ohio State University), Wayne Rothbaum, Raquel Izumi, Deborah M. Stephens(University of North Carolina at Chapel Hill), Jesse McGreivy(Pharmacyclics (United States)), John M. Pagel(University of Washington), Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Bonnie K. Harrington(The Ohio State University), Todd Covey, Maria Fardis(Pharmacyclics (United States)), Brian J. Lannutti, Farrukh T. Awan(The Ohio State University), Ahmed Hamdy(FX Palo Alto Laboratory), Jorge Chaves(Northwest Medical Specialties), Anna Schuh(National Institute for Health Research), Jacqueline C. Barrientos(Northwell Health), Allard Kaptein, Paolo Ghia(Vita-Salute San Raffaele University), William G. Wierda(The University of Texas MD Anderson Cancer Center), Thomas G. Diacovo, Xiaolin Wang(University of Science and Technology of China), Jane Huang, Jeffrey A. Jones(The Ohio State University), Dave Johnson, Susan O’Brien(University of California, Irvine)
Cited by 890
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|9.9k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k